longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response.. 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * GLECKEL LOUIS MD			2. Issuer Name and Ticker or Trading Symbol ProPhase Labs, Inc. [PRPH]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director 10% Owner						
(Last) (First) (Middle) 711 STEWART AVENUE,, SUITE 200				3. Date of Earliest Transaction (Month/Day/Year) 07/01/2022							e title below)		r (specify below)		
(Street) GARDEN CITY,, NY 11530				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
	(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu					s Acquired,	uired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)						Date, if Code (Instr		(A	Securities Acquait or Disposed on Str. 3, 4 and 5)	of (D) Own Tran	Amount of Securities Beneficially wined Following Reported ransaction(s) nstr. 3 and 4)		d (Ownership of Form:	Nature f Indirect eneficial
								e V Aı	(A) or (D)	Price	r. 3 and 4)		or (I)	Indirect (In	vnership istr. 4)
Reminder:								in this fo	who respon orm are not re a currently	equired to	respond	unless the		ed SEC 14	74 (9-02)
Reminder:								in this fo	orm are not r	equired to	respond	unless the		ed SEC 14	74 (9-02)
1. Title of Derivative Security	2. Conversion or Exercise		3A. Deemed Execution Date, if any	4. Transac Code	ts, call 5 tion o	ls, warr 5. Number of Deriva Securities	er ative	in this for displays nired, Disposoptions, cor 6. Date Exer	orm are not rest a currently vessed of, or Beneavertible securicisable and Date	equired to valid OMB ficially Own ities) 7. Title and of Underlying Securities	respond control r ned Amount	8. Price of Derivative Security	9. Number of Derivative Securities	10. Ownership Form of	11. Natu of Indire Benefici
1. Title of Derivative	2. Conversion	Date	3A. Deemed Execution Date, if	4. Transac Code	tion 5 S A O O (I	ls, warr 5. Number 1 Deriva	er ative s l (A) sed	in this for displays nired, Disposoptions, core 6. Date Exered Expiration I	orm are not rest a currently vessed of, or Beneavertible securicisable and Date	equired to valid OMB ficially Own ities) 7. Title and of Underlyi	respond control r ned Amount	8. Price of Derivative	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	To 10. Ownership Form of Derivative Security: Direct (D) or Indirect (D) (I)	11. Natu of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion 5 S A O O (I	Is, warr i. Number i. Number i. Securities i. Securities i. Number i. Securities i. Secur	er ntive s l (A) sed 4,	in this for displays tired, Disposoptions, cor 6. Date Exer Expiration I (Month/Day	orm are not rest a currently vessed of, or Beneavertible securicisable and Date	equired to valid OMB ficially Own ities) 7. Title and of Underlying Securities	respond control r ned Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natu of Indire Benefici Ownersh (Instr. 4)

Reporting Owners

D (1 0 N)	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
GLECKEL LOUIS MD 711 STEWART AVENUE, SUITE 200 GARDEN CITY,, NY 11530	X					

Signatures

/s/ Louis Gleckel, MD	07/05/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The transaction reported in this row involves a grant by the Issuer to the Reporting Person of a stock option to purchase the Issuer's common stock, with such option vesting in four equal quarterly installments over one year, with the first quarterly installment to vest on September 30, 2022 and each additional installment to vest quarterly thereafter, provided the recipient (1) continues to serve as a non-employee director of the Issuer on each such vesting date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of July 1, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.